Literature DB >> 6126541

Cardiovascular effects in the rat of ketanserin, a novel 5-hydroxytryptamine receptor blocking agent.

B Persson, T Hedner, M Henning.   

Abstract

Following intravenous administration of ketanserin (0.3-10 mg kg-1) to conscious or anaesthetized normotensive and spontaneously hypertensive rats there were dose-dependent blood pressure reductions but no compensatory tachycardia. Intracerebroventricular administration of ketanserin (25-500 microgram) had inconsistent and largely insignificant cardiovascular effects. In a dose range where it produces hypotension ketanserin antagonized the pressor responses to adrenaline and noradrenaline as well as to 5-hydroxytryptamine in monoamine depleted and spinalized rats. It is suggested that the hypotensive action of ketanserin in the rat does not involve a central mechanism but a peripheral alpha-adrenolytic action is implicated.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6126541     DOI: 10.1111/j.2042-7158.1982.tb04753.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  11 in total

1.  Contribution of serotonergic systems to maintenance of blood pressure in anaesthetised normotensive Wistar Kyoto and conscious spontaneously hypertensive rats.

Authors:  B G Schulz; G Schröder; G Stock
Journal:  Drugs       Date:  1988       Impact factor: 9.546

2.  Antihypertensive effects of chronic 5-hydroxytryptamine (5-HT2) receptor blockade with irindalone in the spontaneously hypertensive rat.

Authors:  K Gradin; T Hedner; B Persson
Journal:  J Neural Transm Gen Sect       Date:  1991

3.  Effects of ketanserin and DOI on spontaneous and 5-HT-evoked peristalsis of the pig ureter in vivo.

Authors:  D S Hauser; M Mevissen; R Weiss; C J Portier; G Scholtysik; U E Studer; H Danuser
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

4.  Ketanserin, a novel 5-hydroxytryptamine antagonist: monotherapy in essential hypertension.

Authors:  T Hedner; B Persson; G Berglund
Journal:  Br J Clin Pharmacol       Date:  1983-08       Impact factor: 4.335

5.  Haemodynamic and humoral responses to chronic ketanserin treatment in essential hypertension.

Authors:  R Fagard; R Fiocchi; P Lijnen; J Staessen; E Moerman; A de Schaepdryver; A Amery
Journal:  Br Heart J       Date:  1984-02

6.  Ketanserin in essential hypertension: effects during rest and exercise.

Authors:  B Persson; T Hedner; G Berglund
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Hypersensitivity of mesenteric veins to 5-hydroxytryptamine- and ketanserin-induced reduction of portal pressure in portal hypertensive rats.

Authors:  S A Cummings; R J Groszmann; A J Kaumann
Journal:  Br J Pharmacol       Date:  1986-11       Impact factor: 8.739

8.  Ketanserin in combination with beta-adrenergic receptor blocking agents in the treatment of essential hypertension.

Authors:  T Hedner; B Persson
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

9.  Hyperthermia induced by m-CPP in the rat and its modification by antidepressant treatments.

Authors:  K M Wozniak; C S Aulakh; J L Hill; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

10.  Antihypertensive mechanism of action of ketanserin and some ketanserin analogues in the spontaneously hypertensive rat.

Authors:  A Pettersson; K Gradin; T Hedner; B Persson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-06       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.